Improved cerebrovascular function and reduced histological damage with darbepoietin alfa administration after cortical impact injury in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 2, 2011, Pages 451-456

  Cherian, Leela ^a   Goodman, J Clay ^a   Robertso, Claudia ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN FUNCTION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG EFFICACY; HEMODYNAMICS; HISTOPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; TRAUMATIC BRAIN INJURY;

ANATOMY, CROSS-SECTIONAL; ANIMALS; ARGININE; BRAIN INJURIES; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; HEMATINICS; LASER-DOPPLER FLOWMETRY; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; RATS; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY;

EID: 79955025073     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.176602     Document Type: Article

References (40)

1. Adembri C, Massagrande A, Tani A, Miranda M, Margheri M, De Gaudio R, and Pellegrini-Giampietro DE (2008) Carbamylated erythropoietin is neuroprotective in an experimental model of traumatic brain injury. Crit Care Med 36:975-978.
2. Alafaci C, Salpietro F, Grasso G, Sfacteria A, Passalacqua M, Morabito A, Tripodo E, Calapai G, Buemi M, and Tomasello F (2000) Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage. Eur J Pharmacol 406:219-225.
3. Aydin A, Genç K, Akhisaroglu M, Yorukoglu K, Gokmen N, and Gonullu E (2003) Erythropoietin exerts neuroprotective effect in neonatal rat model of hypoxicischemic brain injury. Brain Dev 25:494-498. (Pubitemid 37485656)
4. Baker JE, Kozik D, Hsu AK, Fu X, Tweddell JS, and Gross GJ (2007) Darbepoetin alfa protects the rat heart against infarction: Dose-response, phase of action, and mechanisms. J Cardiovasc Pharmacol 49:337-345. (Pubitemid 47000307)
5. Banks WA, Jumbe NL, Farrell CL, Niehoff ML, and Heatherington AC (2004) Passage of erythropoietic agents across the blood-brain barrier: A comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur J Pharmacol 505:93-101. (Pubitemid 39535680)
6. Belayev L, Khoutorova L, Zhao W, Vigdorchik A, Belayev A, Busto R, Magal E, and Ginsberg MD (2005) Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats. Stroke 36:1071-1076.
7. Brendt P, Frey U, Adamzik M, Schäfer ST, and Peters J (2009) Darbepoetin alpha, a long-acting erythropoietin derivate, does not alter LPS evoked myocardial depression and gene expression of Bax, Bcl-Xs, Bcl-XL, Bcl-2, and TNF-α. Shock 31:50-54.
8. Brines M and Cerami A (2008) Erythropoietin-mediated tissue protection: Reducing collateral damage from the primary injury response. J Intern Med 264:405-432.
9. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, et al. (2004) Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor. Proc Natl Acad Sci USA 101:14907-14912. (Pubitemid 39410773)
10. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, et al. (2008) Nonerythropoietic, tissue- protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 105:10925-10930.
11. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, and Cerami A (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97:10526-10531.
12. Calapai G, Marciano MC, Corica F, Allegra A, Parisi A, Frisina N, Caputi AP, and Buemi M (2000) Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 401:349-356. (Pubitemid 30608719)
13. Catania MA, Marciano MC, Parisi A, Sturiale A, Buemi M, Grasso G, Squadrito F, Caputi AP, and Calapai G (2002) Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. Eur J Pharmacol 437:147-150. (Pubitemid 34219475)
14. Celik M, Gökmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, Genc S, Genc K, Sagiroglu E, Cerami A, et al. (2002) Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 99:2258-2263. (Pubitemid 34169048)
15. Cherian L, Goodman JC, and Robertson C (2007) Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. J Pharmacol Exp Ther 322:789-794. (Pubitemid 47105820)
16. Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C, and Gassmann M (1995) Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 92:3717-3720.
17. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, et al. (2003) Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21:414-421. (Pubitemid 36397662)
18. Emir M, Ozisik K, Cagli K, Misirlioglu M, Ozisik P, Iscan Z, Yildirim E, Kilinc K, and Sener E (2004) Effect of erythropoietin on bcl-2 gene expression in rat cardiac myocytes after traumatic brain injury. Transplant Proc 36:2935-2938. (Pubitemid 41126710)
19. Fishbane S, Ragolia L, Palaia T, Johnson B, Elzein H, and Maesaka JK (2004) Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells. Kidney Int 65:452-458. (Pubitemid 38130639)
20. Gao E, Boucher M, Chuprun JK, Zhou RH, Eckhart AD, and Koch WJ (2007) Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol 293:H60-H68. (Pubitemid 47105059)
21. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, Di Giulio AM, Vardar E, Cerami A, and Brines M (2002) Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 99:9450-9455. (Pubitemid 34764634)
22. Grasso G, Graziano F, Sfacteria A, Carletti F, Meli F, Maugeri R, Passalacqua M, Certo F, Fazio M, Buemi M, et al. (2009) Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage. Neurosurgery 65:763-769; discussion 769-770.
23. Grasso G, Sfacteria A, Meli F, Fodale V, Buemi M, and Iacopino DG (2007) Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res 1182:99-105. (Pubitemid 350086993)
24. Hlatky R, Lui H, Cherian L, Goodman JC, O'Brien WE, Contant CF, and Robertson CS (2003) The role of endothelial nitric oxide synthase in the cerebral hemodynamics after controlled cortical impact injury in mice. J Neurotrauma 20:995-1006. (Pubitemid 37288559)
25. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, and Gobe GC (2006) Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 69:1806-1813. (Pubitemid 43739209)
26. Kanellakis P, Pomilio G, Agrotis A, Gao X, Du XJ, Curtis D, and Bobik A (2010) Darbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common β-chain heteroreceptor. Br J Pharmacol 160:2085-2096.
27. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, et al. (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239-242. (Pubitemid 38886736)
28. Mann C, Lee JH, Liu J, Stammers AM, Sohn HM, Tetzlaff W, and Kwon BK (2008) Delayed treatment of spinal cord injury with erythropoietin or darbepoetin-a lack of neuroprotective efficacy in a contusion model of cord injury. Exp Neurol 211: 34-40.
29. Noguchi CT, Asavaritikrai P, Teng R, and Jia Y (2007) Role of erythropoietin in the brain. Crit Rev Oncol Hematol 64:159-171. (Pubitemid 47496220)
30. Shafi NI, Andresen J, Marrelli SP, and Bryan RM Jr (2008) Erythropoietin potentiates EDHF-mediated dilations in rat middle cerebral arteries. J Neurotrauma 25:257-265. (Pubitemid 351416737)
31. Sinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, Liu L, Busse L, Swift S, Elliott S, and Begley CG (2010) Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 115:4264-4272.
32. Sirén AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, et al. (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 98:4044-4049. (Pubitemid 32249895)
33. Wang XQ and Vaziri ND (1999) Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 33:894-899. (Pubitemid 29140452)
34. Xiong Y, Lu D, Qu C, Goussev A, Schallert T, Mahmood A, and Chopp M (2008) Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice. J Neurosurg 109:510-521.
35. Xiong Y, Mahmood A, Qu C, Kazmi H, Zhang ZG, Noguchi CT, Schallert T, and Chopp M (2010) Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neural erythropoietin receptor. J Neurotrauma 27:205-215.
36. Yatsiv I, Grigoriadis N, Simeonidou C, Stahel PF, Schmidt OI, Alexandrovitch AG, Tsenter J, and Shohami E (2005) Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J 19:1701-1703. (Pubitemid 41429535)
37. Yildirim E, Ozisik K, Solaroglu I, Kaptanoglu E, Beskonakli E, Sargon MF, Kilinc K, and Sakinci U (2005) Protective effect of erythropoietin on type II pneumocyte cells after traumatic brain injury in rats. J Trauma 58:1252-1258. (Pubitemid 41020114)
38. Zhang Y, Xiong Y, Mahmood A, Meng Y, Qu C, Schallert T, and Chopp M (2009) Therapeutic effects of erythropoietin on histological and functional outcomes following traumatic brain injury in rats are independent of hematocrit. Brain Res 1294:153-164.
39. Zhu L, Jin W, Pan H, Hu Z, Zhou J, Hang C, and Shi J (2009a) Erythropoietin inhibits the increase of intestinal labile zinc and the expression of inflammatory mediators after traumatic brain injury in rats. J Trauma 66:730-736.
40. Zhu L, Wang HD, Yu XG, Jin W, Qiao L, Lu TJ, Hu ZL, and Zhou J (2009b) Erythropoietin prevents zinc accumulation and neuronal death after traumatic brain injury in rat hippocampus: In vitro and in vivo studies. Brain Res 1289:96-105.